BNP Paribas Financial Markets
HOWL icon

BNP Paribas Financial Markets’s Werewolf Therapeutics HOWL Stock Holding History

BNP Paribas Financial Markets’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284 Hold
790
– – ﹤0.01% 5733
2026
Q1 		$658 Sell
790
-2
-0.3% -$1 ﹤0.01% 5515
2025
Q4 		$502 Sell
792
-1
-0.1% -$1 ﹤0.01% 5477
2025
Q3 		$1.56K Sell
793
-2,820
-78% -$3.86K ﹤0.01% 5190
2025
Q2 		$3.94K Buy
3,613
+248
+7% +$255 ﹤0.01% 4980
2025
Q1 		$3.27K Sell
3,365
-3,467
-51% -$4.54K ﹤0.01% 4921
2024
Q4 		$10.1K Buy
+6,832
New +$13.9K ﹤0.01% 4842

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets's HOWL Position: Q2 2026 in Review

BNP Paribas Financial Markets held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 790 shares worth $284. The position accounts for ﹤0.01% of the portfolio, ranked #5733.

BNP Paribas Financial Markets first reported a position in HOWL in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.1K in Q4 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • BNP Paribas Financial Markets held 790 shares of Werewolf Therapeutics worth $284 as of Q2 2026.
  • BNP Paribas Financial Markets left its Werewolf Therapeutics share count unchanged in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5733 holding.
  • BNP Paribas Financial Markets first reported a position in Werewolf Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Werewolf Therapeutics position peaked at $10.1K in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.